Zevra Therapeutics Inc. (ZVRA)
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZVRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $521.26M
- P/E (TTM)
- 7.18
- Forward P/E
- 9.84
- EPS (TTM)
- $1.22
- Dividend yield
- None
- 52-week range
- 8.01 – 15.04
- Day range
- 8.70 – 9.20
- Volume / Avg
- 1.15M / 954.53K
- Beta
- —
- Shares outstanding
- 59.50M
52-week range
ZVRA stock today
Shares of Zevra Therapeutics (ZVRA) finished lower on Nov 20 at $8.76, a drop of 3.42% or $0.31 per share, versus the S&P 500's 3.70% decline. Shares are 41.7% below their 52-week high of $15.04, set on Jul 8, 2026 and 9.4% above the 52-week low of $8.01, near the bottom of the past year's range. ZVRA is down 2.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.9%.
Zevra Therapeutics trades at 7.2x its trailing twelve-month earnings per share of $1.22. Its forward P/E of 9.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Zevra Therapeutics
Company profileZevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Neil F. McFarlane
- Headquarters
- Boston, MA
- Employees
- 61
- Website
- zevra.com
Financial highlights
Full financialsIn fiscal 2025, Zevra Therapeutics generated $106.5 million in revenue, up 350.9% from fiscal 2024. Net income was $83.2 million, for a net margin of 78.2% versus a median of -167.7% in the prior 5 years. Gross margin was 84.5% (up from 68.6%) and operating margin -59.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $106.47M | $23.61M | $27.46M | $10.16M | $28.65M |
| Growth | +350.91% | -14.02% | +170.26% | -64.53% | +115.61% |
| Net income | $83.23M | $-105.51M | $-46.05M | $-26.77M | $-8.55M |
| EPS (diluted) | $1.35 | $-2.28 | — | — | $-2.11 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$23.00+162.56%
- Strong buy 2
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.26 vs $0.14
- Surprise
- +85.71%
ZVRA news
All ZVRA news- Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare ConferenceGlobeNewswire
- Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionGlobeNewswire
- Noteworthy Tuesday Option Activity: MARA, ZVRA, CRWVNasdaqMARA, ZVRA, CRWV
- Zevra (ZVRA) Q3 2026 Earnings Call TranscriptNasdaq
- Zevra Reports Third Quarter 2026 Financial Results and Corporate UpdateNasdaq
- Zevra Therapeutics, Inc. GAAP EPS of $0.26 beats by $0.11, revenue of $37.8M beats by $0.39MSeeking Alpha
- Zevra Reports Third Quarter 2026 Financial Results and Corporate UpdateGlobeNewswire
- Notable Monday Option Activity: LOVE, SNOW, ZVRANasdaqLOVE, SNOW, ZVRA
Zevra Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs ZVRA |
| WVEWave Life Sciences Inc. | 2.56 | -5.88% | $504.91M | vs ZVRA |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs ZVRA |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs ZVRA |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs ZVRA |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs ZVRA |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs ZVRA |
| HELPHelus Pharma Inc. | 6.11 | -9.88% | $487.68M | vs ZVRA |
Indexes, lists and sector
Zevra Therapeutics stock FAQ
What is Zevra Therapeutics's stock price today?
ZVRA last traded at $8.76 as of Nov 20, 4:00 PM EST, down 3.42% on the day. Prices are delayed at least 15 minutes.
Does Zevra Therapeutics pay a dividend?
No. Zevra Therapeutics does not currently pay a regular cash dividend.
What is ZVRA's P/E ratio?
ZVRA trades at a trailing P/E ratio of 7.18 and a forward P/E of 9.84.
Who is Zevra Therapeutics's CEO?
Mr. Neil F. McFarlane is the chief executive officer of Zevra Therapeutics Inc., which has about 61 employees.
Has ZVRA ever split its stock?
Yes. The most recent ZVRA stock split was a 1-for-16 split on Dec 28, 2020.
What is the ZVRA 52-week high?
The 52-week high for ZVRA is $15.04 and the 52-week low is $8.01. The stock is currently 41.7% below its high.